Bardoxolone brings Nrf2-based therapies to light

Antioxidants and Redox Signaling

Volumn 19, Issue 5, 2013, Pages 517-518

  Zhang, Donna D ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE; PLACEBO; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CHRONIC KIDNEY DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOBIOTIC STRESS;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879908171     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5118     Document Type: Article

References (9)

1. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, and Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 8: 2711-2714, 1998
2. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007
3. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, and Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789-4798, 2005
4. Liby KT and Sporn MB. Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64: 972-1003, 2012
5. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, and Warnock DG. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011
6. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, and Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 6: 154-162, 2007
7. Yore MM, Kettenbach AN, Sporn MB, Gerber SA, and Liby KT. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One 6: E22862, 2011
8. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789, 2006
9. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, and Zhang DD. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60: 3055-3066, 2011